Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ERBB2”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT02067741
What this trial is testing

CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer

Who this might be right for
Metastatic Breast AdenocarcinomaBreast Cancer
Swiss Cancer Institute 29
Testing effectiveness (Phase 2)Study completedNCT01674062
What this trial is testing

Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 95
Testing effectiveness (Phase 2)Looking for participantsNCT06374459
What this trial is testing

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Who this might be right for
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Washington University School of Medicine 152
Large-scale testing (Phase 3)Looking for participantsNCT06313983
What this trial is testing

A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer

Who this might be right for
Breast Cancer
Tianjin Hemay Pharmaceutical Co., Ltd 339
Testing effectiveness (Phase 2)WithdrawnNCT01137994
What this trial is testing

A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline
Testing effectiveness (Phase 2)Temporarily pausedNCT05656131
What this trial is testing

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Who this might be right for
Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
wang shusen 80
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07753954
What this trial is testing

Medical Imaging to Re-evaluate Elacestrant Clinical Usage

Who this might be right for
ER+ / HER2- Advanced Breast Cancer
Jules Bordet Institute 160
Not applicableStudy completedNCT01160094
What this trial is testing

Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)

Who this might be right for
Cancer
Novartis 288
Not applicableEnded earlyNCT03738553
What this trial is testing

Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy

Who this might be right for
HER2-positive Breast Cancer
University of Washington 13
Testing effectiveness (Phase 2)Study completedNCT00136539
What this trial is testing

Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

Who this might be right for
Breast Cancer
Harold J. Burstein, MD, PhD 41
Testing effectiveness (Phase 2)Looking for participantsNCT07335081
What this trial is testing

CtDNA in HER2+ EBC Neoadjuvant Treatment

Who this might be right for
Breast Cancer
Shanghai Jiao Tong University School of Medicine 60
Testing effectiveness (Phase 2)Ended earlyNCT02154529
What this trial is testing

Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Who this might be right for
HER-2 Positive Breast CancerMetastatic Malignant Neoplasm to Brain
Kadmon Corporation, LLC 17
Testing effectiveness (Phase 2)Ended earlyNCT01528345
What this trial is testing

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 97
Large-scale testing (Phase 3)UnknownNCT02383030
What this trial is testing

Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients

Who this might be right for
Metastatic Breast Cancer
Consorzio Oncotech 156
Testing effectiveness (Phase 2)UnknownNCT04389073
What this trial is testing

Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

Who this might be right for
Metastatic Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 138
Testing effectiveness (Phase 2)Looking for participantsNCT07492394
What this trial is testing

Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer

Who this might be right for
Breast Cancer
Hebei Medical University Fourth Hospital 60
Early research (Phase 1)WithdrawnNCT00017537
What this trial is testing

Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer

Who this might be right for
Breast CancerGastric CancerLung Cancer+2 more
University of Alabama at Birmingham
Large-scale testing (Phase 3)Study completedNCT03286842
What this trial is testing

To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

Who this might be right for
HER2-ve Metastatic Breast CancerGermline BRCA1/2 MutationsSomatic BRCA1/2 Mutations
AstraZeneca 256
Large-scale testing (Phase 3)Looking for participantsNCT05754853
What this trial is testing

MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Who this might be right for
Advanced or Metastatic Urothelium Cancer
Shanghai Miracogen Inc. 290
Not applicableStudy completedNCT04498481
What this trial is testing

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

Who this might be right for
Breast Cancer
Pfizer 1
Next Page